Data from Mehra et al. (2020-05-29), "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis"
- 1. Brigham and Women's Hospital, Boston, MA, USA
- 2. Surgisphere Corporation, Chicago, IL, USA
- 3. University Hospital Zurich, Zurich, Switzerland
- 4. University of Utah, Salt Lake City, UT, USA
Description
Recent reports have identified errors and implausible results in the title paper, few of which have been corrected to date. To facilitate analysis, I provide a spreadsheet containing all data from tables in the corrected version (2020-05-29), from both the main text (html) and supporting information (PDF).
The data is uploaded to this publicly-funded repository with the permission of the copyright holder: "Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories ... with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source." Text and data mining are also permitted: "These articles are also available to download with rights for full text and data mining, re-use and analyses for as long as needed."
Files
Files
(42.6 kB)
Name | Size | Download all |
---|---|---|
md5:a6eff2f1a05c021893ddaa96b576b1f2
|
42.6 kB | Download |
Additional details
Related works
- Is supplement to
- Journal article: 10.1016/S0140-6736(20)31180-6 (DOI)
References
- Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, http://doi.org/ggwzsb
- James Watson, 182 signatories. (2020). An open letter to Mehra et al and The Lancet. Zenodo. http://doi.org/dw8t